Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Calling all Speculators

<If TPL mingled their non-MMP patents with the J3 suit at the expense of PTSC shareholdes, and PTSC agreed (remember we are one of the parties), guilty of gross negligence could be asserted at TPL/PTSC management by PTSC shareholdes.>

I assumed that if a TPL license was part of any deal, it would have to have been for nothing or next to nothing. No incentive to J2.5 otherwise. What perhaps was going on was neither side would budge on the amount of money to settle out of court. TPL added more value to the settlement rather than come down on amount of $ being asked for? I hope anyway. IMHO Opty

Share
New Message
Please login to post a reply